Abstract P2-08-03: Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer

A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer.

10.1158/0008-5472.sabcs-16 ◽

2009 ◽

Cited By ~ 3

Author(s):

MJ Ellis ◽

F Dehdahti ◽

A Kommareddy ◽

S Jamalabadi-Majidi ◽

R Crowder ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Aromatase Inhibitor ◽

Low Dose ◽

High Dose ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

Abstract P4-02-05: A Phase II Trial of Fulvestrant and RAD001 (Everolimus) in Patients with Metastatic Estrogen Receptor Positive Breast Cancer after Aromatase Inhibitor Failure; a Study in Progress

10.1158/0008-5472.sabcs10-p4-02-05 ◽

2010 ◽

Cited By ~ 3

Author(s):

F Badin ◽

E Romond ◽

M Chambers ◽

B Shelton ◽

S Birk ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Phase Ii Trial ◽

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

Cancer ◽

10.1002/cncr.22789 ◽

2007 ◽

Vol 110 (2) ◽

pp. 244-254 ◽

Cited By ~ 197

Author(s):

Vladimir F. Semiglazov ◽

Vladislav V. Semiglazov ◽

Garik A. Dashyan ◽

Elena K. Ziltsova ◽

Vadim G. Ivanov ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Randomized Trial ◽

Endocrine Therapy ◽

Phase 2 ◽

Primary Endocrine Therapy ◽

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

Breast Cancer Research ◽

10.1186/s13058-020-01286-7 ◽

2020 ◽

Vol 22 (1) ◽

Author(s):

Swaathi Jayaraman ◽

Xiaonan Hou ◽

Mary J. Kuffel ◽

Vera J. Suman ◽

Tanya L. Hoskin ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Antitumor Activity ◽

Aromatase Inhibitor ◽

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30817-4 ◽

2020 ◽

Vol 21 (3) ◽

pp. 345-357 ◽

Cited By ~ 27

Author(s):

Robert H Jones ◽

Angela Casbard ◽

Margherita Carucci ◽

Catrin Cox ◽

Rachel Butler ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Oestrogen Receptor ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomised Controlled ◽

Abstract LB-423: Whole genome comparisons of pre- and post- aromatase inhibitor treatment in estrogen receptor positive breast cancer

10.1158/1538-7445.am2012-lb-423 ◽

2012 ◽

Cited By ~ 1

Author(s):

Matthew J. Ellis ◽

Ding Li ◽

Dong Shen ◽

Jingqin Luo ◽

Vera J. Suman ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Aromatase Inhibitor ◽

Whole Genome ◽

Aromatase Inhibitor Treatment ◽

Genome Comparisons ◽

Inhibitor Treatment ◽

The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.07.007 ◽

2019 ◽

Vol 19 (6) ◽

pp. e731-e740 ◽

Cited By ~ 2

Author(s):

R.T. Pavlović ◽

S.M. Janković ◽

J.R. Milovanović ◽

S.M. Stefanović ◽

M.M. Folić ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Aromatase Inhibitor ◽

Meta Analysis ◽

Hormonal Treatment ◽

Inhibitor Therapy ◽

Aromatase Inhibitor Therapy ◽

Vulvovaginal Atrophy ◽

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy

Frontiers in Oncology ◽

10.3389/fonc.2020.00342 ◽

2020 ◽

Vol 10 ◽

Cited By ~ 1

Author(s):

Tomás Reinert ◽

Susana Ramalho ◽

Vivian Castro Antunes de Vasconcelos ◽

Leonardo Roberto Silva ◽

Ana Elisa Ribeiro da Silva ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Aromatase Inhibitor ◽

Endocrine Resistance ◽

Inhibitor Therapy ◽

Common Mechanism ◽

Aromatase Inhibitor Therapy ◽

Esr1 Mutations ◽

Abstract P5-09-16: Contribution of estrone-sulfate to cell proliferation in aromatase inhibitor resistance of estrogen receptor positive breast cancer

10.1158/0008-5472.sabcs13-p5-09-16 ◽

2013 ◽

Author(s):

T Higuchi ◽

M Endo ◽

T Gohno ◽

T Hanamura ◽

T Niwa ◽

...

Keyword(s):

Breast Cancer ◽

Cell Proliferation ◽

Estrogen Receptor ◽

Aromatase Inhibitor ◽

Estrone Sulfate ◽

Aromatase Inhibitor Resistance ◽

Inhibitor Resistance ◽

BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC)

Annals of Oncology ◽

10.1093/annonc/mdw365.01 ◽

2016 ◽

Vol 27 ◽

pp. vi68 ◽

Cited By ~ 5

Author(s):

M. Royce ◽

C. Villanueva ◽

M. Ozguroglu ◽

T. Bachelot ◽

S. Azevedo ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Epidermal Growth